Novo Nordisk A/S has received a positive recommendation from the CHMP for its Wegovy® 7.2 mg single-dose pen, expected to launch in Q3 2026, showing a mean weight loss of 20.7% during trials. This approval is significant as it enhances treatment options for obesity—a considerable advancement for the company.